Sarvin Sanaie

Dr. Sarvin Sanaie

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2018 in Nutrition in Clinical Practice
Verified
Journal Article
Closed access
PDF file
AMAta Mahmoodpoor
Ata Mahmoodpoor
HHHadi Hamishehkar
Hadi Hamishehkar
RARoghaieh Asghari
Roghaieh Asghari
RARamin Abri
Ramin Abri
KSKamran Shadvar
Kamran Shadvar
SSSarvin Sanaie
Sarvin Sanaie

1 October 2013 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
SRSoheila Rezapour-Firouzi
Soheila Rezapour-Firouzi
SASeyed Rafie Arefhosseini
Seyed Rafie Arefhosseini
FMFarhoudi Mehdi
Farhoudi Mehdi
EMEbrahimi-Mamaghani Mehrangiz
Ebrahimi-Mamaghani Mehrangiz
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
FZFatemeh Zamani
Fatemeh Zamani

22 December 2016 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
HHHadi Hamishehkar
Hadi Hamishehkar
FRFarhad Ranjdoost
Farhad Ranjdoost
PAparina asgharian
parina asgharian
AMAta Mahmoodpoor
Ata Mahmoodpoor
SSSarvin Sanaie
Sarvin Sanaie
The consumption of a daily multivitamin among people all over the world is dramatically increasing in recent years. Most of the people believe that if vitamins are not effective, at least they are safe. However, the long term health consequences of vitamins consumption are unknown. This study aimed to assess the side effects and possible harmful and detrimental properties of vitamins and to discuss whether vitamins can be used as safe health products or dietary supplements. We performed a MEDLINE/PubMed, EMBASE, Scopus and Google Scholar search and assessed reference lists of the included studies which were published from 1993 through 2015. The studies, with an emphasis on RCTs (randomized controlled clinical trials), were reviewed. As some vitamins such as fat-soluble vitamins (vitamin A, vitamin D, vitamin E), and also some of the water-soluble vitamins like folic acid may cause adverse events and some like vitamin C is widely taken assuming that it has so many benefits and no harm, we included relevant studies with negative or undesired results regarding the effect of these vitamins on health. Our recommendation is that taking high-dose supplements of vitamins A, E, D, C, and folic acid is not always effective for prevention of disease, and it can even be harmful to the health.

29 July 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KSKamran Shadvar
Kamran Shadvar
NNNader Nader
Nader Nader
NVNoushin Vahed
Noushin Vahed
SSSarvin Sanaie
Sarvin Sanaie
AIAfshin Iranpour
Afshin Iranpour
FRFarshid Rahimi-Bashar
Farshid Rahimi-Bashar
The aim of this study was to evaluate the prognostic value of the Lactate to Albumin (L/A) ratio compared to that of lactate and lactate clearance in predicting outcomes in patients with septic shock. This was a multi-center observational study of adult patients with septic shock, who admitted to intensive care units (ICUs) at Shohada and Imam Reza Hospitals, Tabriz, Iran, between Sept 2018 and Jan 2021. The area under the curve (AUC) of receiver operating characteristic (ROC) curve and multivariate logistic regression analyses were used to explore associations of the L/A ratio, lactate and lactate clearance on the primary (mortality) and secondary outcomes [ICU length of stay (LOS), duration of mechanical ventilation (MV), need of renal replacement therapy (RRT) and duration of using vasopressors] at baseline, 6 h and 24 h of septic shock recognition. Best performing predictive value for mortality were related to lactate clearance at 24 h, L/A ratio at 6 h and lactate levels at 24 h with (AUC 0.963, 95% CI 0.918–0.987, P < 0.001), (AUC 0.917, 95% CI 0.861–0.956, P < 0.001), and (AUC 0.904, 95% CI 0.845–0.946, P < 0.001), respectively. Generally, the lactate clearance at 24 h had better prognostic performance for mortality and duration of using vasopressor. However, the L/A ratio had better prognostic performance than serum lactate and lactate clearance for RRT, ICU LOS and MV duration.

21 February 2019 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
MGMorteza Ghojazadeh
Morteza Ghojazadeh
SSSarvin Sanaie
Sarvin Sanaie
SPSeyed Pouya Paknezhad
Seyed Pouya Paknezhad
SFSahba-Sadat Faghih
Sahba-Sadat Faghih
HSHassan Soleimanpour
Hassan Soleimanpour
Purpose: Ketamine-propofol combination (ketofol) is being used to provide a safe and effective procedural sedation (PS) in emergency department (ED) and may theoretically have beneficial effects since using lower doses of each drug may result in a reduction of the adverse events of both agents while maintaining optimal conditions for performing procedures. This systematic review was conducted to evaluate the efficacy, advantages and disadvantages of these two drugs for PS. Methods: The PRISMA statement was used for this systematic review. We searched the databases of PubMed, Scopus, ProQuest, Medline (Ovid) from 1990 to August 2017 for randomized clinical trials (RCTs) in which the study population aged ≥18 and was referred to ED. Full-texts of the studies performed in adults that were published in English were reviewed for inclusion. Both authors independently evaluated all studies. Five articles were eligible for the meta-analysis based on their common outcomes. Results: The total number of subjects was 1250, of which 635 were treated with propofol and 615 were treated with ketofol. Although two of the five studies showed a better quality of sedation with ketofol, the other three did not find any significant difference between propofol and ketofol. This systematic review found a lower incidence of respiratory adverse effects in ketofol group than propofol group. Conclusion: Ketamine/propofol mixture (ketofol) has less respiratory adverse effects than propofol alone in ED procedural sedation.

30 November 2024 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
MHMohammad-Salar Hosseini
Mohammad-Salar Hosseini
SSSarvin Sanaie
Sarvin Sanaie
AMAta Mahmoodpoor
Ata Mahmoodpoor
SBSaba Jabbari Beyrami
Saba Jabbari Beyrami
HBHossein Jabbari Beyrami
Hossein Jabbari Beyrami
MRMahshid Kuchaki Rafsanjani
Mahshid Kuchaki Rafsanjani
Xerostomia, generally addressed as dry mouth, poses significant challenges to patients’ quality of life, particularly in the context of cancer treatment. Although various medications and interventions, including salivary substitutes and stimulants, muscarinic agonists, antineoplastic detoxifying agents, anti-inflammatory agents, superoxide dismutase mimetics, mesenchymal stem cells, submandibular gland transfer, intensity-modulated radiation therapy, dose fractionation, transcutaneous electrical nerve stimulation, hyperbaric oxygen therapy, photobiomodulation, acupuncture, and nutritional interventions, have been proposed for this condition, no approved or definite treatments are currently available. Moreover, the evidence supporting the efficacy of proposed interventions remains limited and subject to controversy in terms of safety, efficacy, and optimal protocol. This review provides a comprehensive insight into cancer treatment-related xerostomia, underlying its pathophysiology, etiology, clinical manifestation, and therapeutic options, providing a clinical guide for clinicians to adopt a patient-tailored approach to cancer treatment-related xerostomia and offering vision on current ongoing and future studies in the field.